Update on capecitabine alone and in combination regimens in colorectal cancer patients

N. Silvestris; E. Maiello; F. De Vita; S. Cinieri; D. Santini; A. Russo; S. Tommasi; A. Azzariti; G. Numico; S. Pisconti; D. Petriella; V. Lorusso; A. Millaku; G. Colucci

doi:10.1016/S0305-7372(10)70020-7

Update on capecitabine alone and in combination regimens in colorectal cancer patients

N. Silvestris, E. Maiello, F. De Vita, S. Cinieri, D. Santini, A. Russo, S. Tommasi, A. Azzariti, G. Numico, S. Pisconti, D. Petriella, V. Lorusso, A. Millaku, G. Colucci

Research output: Contribution to journal › Article › peer-review

Abstract

Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients.

Original language	English
Journal	Cancer Treatment Reviews
Volume	36
Issue number	SUPPL. 3
DOIs	https://doi.org/10.1016/S0305-7372(10)70020-7
Publication status	Published - Nov 2010

Keywords

Adjuvant
Bevacizumab
Capecitabine
Cetuximab
Colorectal carcinoma
Irinotecan
Metastatic
Neoadjuvant
Oxaliplatin
Radiotherapy

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/S0305-7372(10)70020-7

Cite this

Update on capecitabine alone and in combination regimens in colorectal cancer patients. / Silvestris, N.; Maiello, E.; De Vita, F.; Cinieri, S.; Santini, D.; Russo, A.; Tommasi, S.; Azzariti, A.; Numico, G.; Pisconti, S.; Petriella, D.; Lorusso, V.; Millaku, A.; Colucci, G.

In: Cancer Treatment Reviews, Vol. 36, No. SUPPL. 3, 11.2010.

Research output: Contribution to journal › Article › peer-review

@article{b654d68b02fb437fb3c3250814c0b66e,

title = "Update on capecitabine alone and in combination regimens in colorectal cancer patients",

abstract = "Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients.",

keywords = "Adjuvant, Bevacizumab, Capecitabine, Cetuximab, Colorectal carcinoma, Irinotecan, Metastatic, Neoadjuvant, Oxaliplatin, Radiotherapy",

author = "N. Silvestris and E. Maiello and {De Vita}, F. and S. Cinieri and D. Santini and A. Russo and S. Tommasi and A. Azzariti and G. Numico and S. Pisconti and D. Petriella and V. Lorusso and A. Millaku and G. Colucci",

year = "2010",

month = nov,

doi = "10.1016/S0305-7372(10)70020-7",

language = "English",

volume = "36",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "SUPPL. 3",

}

TY - JOUR

T1 - Update on capecitabine alone and in combination regimens in colorectal cancer patients

AU - Silvestris, N.

AU - Maiello, E.

AU - De Vita, F.

AU - Cinieri, S.

AU - Santini, D.

AU - Russo, A.

AU - Tommasi, S.

AU - Azzariti, A.

AU - Numico, G.

AU - Pisconti, S.

AU - Petriella, D.

AU - Lorusso, V.

AU - Millaku, A.

AU - Colucci, G.

PY - 2010/11

Y1 - 2010/11

N2 - Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients.

AB - Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients.

KW - Adjuvant

KW - Bevacizumab

KW - Capecitabine

KW - Cetuximab

KW - Colorectal carcinoma

KW - Irinotecan

KW - Metastatic

KW - Neoadjuvant

KW - Oxaliplatin

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=78649737891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649737891&partnerID=8YFLogxK

U2 - 10.1016/S0305-7372(10)70020-7

DO - 10.1016/S0305-7372(10)70020-7

M3 - Article

C2 - 21129610

AN - SCOPUS:78649737891

VL - 36

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - SUPPL. 3

ER -

Update on capecitabine alone and in combination regimens in colorectal cancer patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this